Council Of Europe Turns The Screw On Drug Pricing – And More
This article was originally published in Scrip
The pressure on pharmaceutical companies to justify the prices they charge for new drugs just seems to keep on growing. The Council of Europe, a human rights organization encompassing no less than 47 member countries, has said that greater transparency is needed on the actual R&D costs that lie beneath "exorbitant" prices of some medicines, particularly those for cancer and hepatitis C.
You may also be interested in...
Progress is being made towards the implementation of the EU’s new patent system, but the UK’s insistence on severing all ties with the European Court could spell the end for its participation.
The recruitment process for the new executive director of the European Medicines Agency seems to be running to schedule.
Russia’s new drug traceability system won’t now be implemented until July, but companies that are ready and able are being encouraged to put the system through its paces in order to flush out any glitches.